Pulmonary Fibrosis News and Research

RSS

Genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for lung disease

A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.

22 May 2013

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania.

22 May 2013

Genetic variation helps predict survival in some cases of pulmonary fibrosis, study finds

Research into genetic features of pulmonary fibrosis by physicians and scientists at the University of Colorado School of Medicine may lead to improved treatment of this deadly lung disease, according to a paper published online by JAMA.

22 May 2013

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.

20 May 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Study identifies seven new genetic regions associated with pulmonary fibrosis

A new genome-wide association study of more than 6,000 people has identified seven new genetic regions associated with pulmonary fibrosis. In findings published online in Nature Genetics on April 14, 2013, researchers at National Jewish Health, the University of Colorado and several other institutions found a number of genes associated with host defense, cell-cell adhesion and DNA repair, which provide clues to possible mechanisms underlying this currently untreatable disease.

20 Apr 2013

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in the risk of death.

17 Apr 2013

Study finds genetic variation is associated with pulmonary fibrosis risk

A newly published study of patients with pulmonary fibrosis has discovered multiple genetic variations that should help with future efforts to treat the disease.

16 Apr 2013

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

Pulmonary fibrosis is a chronic, deadly disease that affects five million people worldwide. It is irreversible, its cause is poorly understood, and it has a median survival of only about 3 years.

15 Apr 2013

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Investigators at the University of Alabama at Birmingham (UAB) have unlocked another piece of the puzzle surrounding idiopathic pulmonary fibrosis, an often fatal lung disease with no cure and no effective treatments.

25 Mar 2013

CPF and PFF to partner with ATS to fund pulmonary fibrosis research

The Coalition for Pulmonary Fibrosis, the Pulmonary Fibrosis Foundation, and the American Thoracic Society-the world's leading professional organization for pulmonary, critical care and sleep medicine-today announced that the CPF and the PFF will again partner with the ATS to fund pulmonary fibrosis research.

21 Mar 2013

Scientists identify mechanosensitive cellular signaling pathway in myofibroblasts

Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, and, eventually, heart failure.

24 Feb 2013

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status.

24 Feb 2013

Researchers explore cellular signals produced by the body in response to traumatic injury

When it comes to healing the terrible wounds of war, success may hinge on the first blood clot - the one that begins forming on the battlefield right after an injury. Researchers exploring the complex stream of cellular signals produced by the body in response to a traumatic injury believe the initial response - formation of a blood clot - may control subsequent healing.

18 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).

3 Jan 2013

Small numbers of ANA- and RP-negative patients with systemic sclerosis

There exists a very small subgroup of patients with systemic sclerosis who lack circulating antinuclear antibodies and who do not have Raynaud's phenomenon, research shows.

31 Dec 2012

First U.S. breathing lung transplant performed in Ronald Reagan UCLA Medical Center

First there was the "heart in a box," a revolutionary experimental technology that allows donor hearts to be delivered to transplant recipients warm and beating rather than frozen in an ice cooler. Now that same technology is being used to deliver "breathing lungs."

27 Nov 2012

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.

21 Nov 2012

Pulmonary Fibrosis News and Research

Genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for lung disease

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Genetic variation helps predict survival in some cases of pulmonary fibrosis, study finds

Boehringer Ingelheim to highlight respiratory research work at ATS 2013

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

Study identifies seven new genetic regions associated with pulmonary fibrosis

Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients

Study finds genetic variation is associated with pulmonary fibrosis risk

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

Scientists identify potential treatment for idiopathic pulmonary fibrosis

CPF and PFF to partner with ATS to fund pulmonary fibrosis research

Scientists identify mechanosensitive cellular signaling pathway in myofibroblasts

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Researchers explore cellular signals produced by the body in response to traumatic injury

LASAG trial for severe influenza initiated

Scientists develop playbook to end devastating impact of fibrotic diseases

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Small numbers of ANA- and RP-negative patients with systemic sclerosis

First U.S. breathing lung transplant performed in Ronald Reagan UCLA Medical Center

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News